Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.21 USD
-0.05 (-1.17%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.20 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vanda Pharmaceuticals Inc. has a market cap of $251.72M, which represents its share price of $4.26 multiplied by its outstanding shares number of 59.09M. As a small-cap company, VNDA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VNDA 4.21 -0.05(-1.17%)
Will VNDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for VNDA
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...
Q2 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Projects Cash Holdings of $280M-$320M by End of 2025
Vanda Pharmaceuticals (VNDA) Reports Lower Q2 Revenue than Expected
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year